LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Testing Market Surpasses USD 2 Billion in 2016

By LabMedica International staff writers
Posted on 16 Jun 2017
The global market for blood testing and typing products used in blood banking/donations of pooled blood reached USD 2.6 billion in 2016, although blood banking is not a fast-growing market and tends to grow only when new diseases are added to testing menu. These are the latest findings of Kalorama Information (New York, NY, USA), an independent medical market research firm.

In its study of the testing markets amidst increased vigilance by U.S. health authorities and cases of Zika and other diseases, Kalorama found three common types of tests related to blood banking:

Immunoassays for HIV, hepatitis B, hepatitis C and syphilis are routinely used to test blood units for blood borne infectious agents. In Latin America, all blood banks also screen donated units for Chagas disease while in some developing countries, blood banks undertake additional screening for Dengue fever and malaria, which are common and deadly in several tropical nations.

Blood grouping and typing reagents and instruments are used by blood transfusion services, hospital and private blood banks and hospital laboratories that prepare blood units for transfusion to patients. Blood bank lab systems require blood tracking to avoid the possibility of the serious error of administering the wrong blood type to a patient.

Nucleic acid testing (NAT) allows blood banks to detect viral contamination, including West Nile Virus, HIV and hepatitis C, sooner and stop them from slipping into blood transfusions, thus making NAT an integral part of efforts to make blood transfusions safer. An estimated 53 million units of blood are screened using NAT. The commonly used NAT assays detect HIV-1 RNA, HCV RNA, HBV DNA, and West Nile Virus (WNV) RNA, and are used to test for West Nile virus, HIV and HCV in almost all the blood drawn in North America, Europe and Japan.

“Although no dramatic change in the testing industry is expected, new guidelines and disease concerns make it a worthwhile time for business planners to revisit test market assumptions,” said Bruce Carlson, Publisher of Kalorama Information.

Related Links:
Kalorama Information

Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Clinical Chemistry System
P780

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more